Nachtsheim Lisa, Jansen L, Shabli S, Arolt C, Quaas A, Klussmann J P, Mayer M, Wolber P
Department of Otorhinolaryngology - Head and Neck Surgery, Medical Faculty, University of Cologne, Cologne, Germany.
Institute of Pathology, Medical Faculty, University of Cologne, Cologne, Germany.
Head Neck. 2025 Jan;47(1):47-56. doi: 10.1002/hed.27880. Epub 2024 Jul 27.
Primary salivary gland carcinomas (SGC) are rare neoplasms that present therapeutic challenges especially in recurrent tumors. The aim of this study was to investigate the incidence and distribution of tumor recurrence, associated risk factors, and survival.
This analysis includes data from 318 patients treated for SGC between 1992 and 2020. Survival analysis was performed using the Kaplan-Meier method. Univariate and multivariate analyses were used to identify risk factors associated with recurrence.
21.7% of the patients developed recurrent disease after a mean of 38.2 months. In multivariate analysis, positive-resection margins, vascular invasion, and tumor localization in the submandibular gland and small salivary glands were independent factors for recurrence. The 5-year overall survival was 67%, the 5-year disease-free survival was 54%.
Tumor recurrence in SGC occurred in one out of five patients. In highly aggressive entities and patients with risk factors, treatment intensification should be considered.
原发性涎腺癌（SGC）是罕见肿瘤，尤其在复发性肿瘤中存在治疗挑战。本研究旨在调查肿瘤复发的发生率和分布、相关危险因素及生存率。
该分析纳入了1992年至2020年间接受SGC治疗的318例患者的数据。采用Kaplan-Meier方法进行生存分析。单因素和多因素分析用于确定与复发相关的危险因素。
21.7%的患者在平均38.2个月后出现疾病复发。多因素分析中，手术切缘阳性、血管侵犯以及肿瘤位于下颌下腺和小涎腺是复发的独立因素。5年总生存率为67%，5年无病生存率为54%。
五分之一的SGC患者会出现肿瘤复发。对于侵袭性强的肿瘤和有危险因素的患者，应考虑强化治疗。
